Skip to main content

Table 1 Baseline patient characteristics

From: NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): from clinical trials to clinical practice

Characteristic Nab-Paclitaxel plus Gemcitabine (range)
AGE (range) 67 (41–77)
  > 70 11 (26,8 %)
SEX
 M 18 (43,9 %)
 F 23 (56,1 %)
PS (Karnofsky)
 100 % 18 (43,9 %)
 80–90 % 14 (34.1 %)
 60–70 % 9 (21,9 %)
PANCREATIC PRIMARY LOCATION
 HEAD 24 (58.5 %)
 BODY/TAIL 17 (41.5 %)
SITE OF METASTASIS
 Lung 10 (24,3 %)
 Node 7 (17 %)
 Liver 30 (73,1 %)
 Peritoneum 5 (12,2 %)
 Bone 1 (2,4 %)
No OF METASTATIC SITES
 1 30 (73,1 %)
  ≥ 2 11 (26,9 %)
BILIARY STENT 9 (21.9 %)
MEDIAN CA19.9 469 U/I (17.4–61546)
PREVIOUS SURGERY 11 (26.8 %)
PREVIOUS ADJUVANT GEMCITABINE 10 (24.3 %)